Sanara MedTech FY2025 EPS Forecast Boosted by HC Wainwright

Sanara MedTech Inc. (NASDAQ:SMTI) – Research analysts at HC Wainwright upped their FY2025 EPS estimates for Sanara MedTech in a research note issued to investors on Monday, January 26th. HC Wainwright analyst Y. Chen now anticipates that the company will post earnings of $0.20 per share for the year, up from their prior forecast of $0.19. HC Wainwright currently has a “Buy” rating and a $36.00 price target on the stock. The consensus estimate for Sanara MedTech’s current full-year earnings is ($1.10) per share.

A number of other brokerages also recently weighed in on SMTI. Zacks Research downgraded Sanara MedTech from a “strong-buy” rating to a “hold” rating in a report on Tuesday, January 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Sanara MedTech in a research report on Thursday. Finally, Wall Street Zen lowered Sanara MedTech from a “buy” rating to a “hold” rating in a research report on Saturday, November 1st. Two research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and an average price target of $41.00.

Sanara MedTech Trading Down 2.3%

NASDAQ SMTI opened at $21.25 on Tuesday. The firm’s 50 day moving average price is $22.84 and its two-hundred day moving average price is $27.28. The stock has a market cap of $189.13 million, a price-to-earnings ratio of -5.04 and a beta of 1.06. Sanara MedTech has a twelve month low of $18.90 and a twelve month high of $37.91. The company has a debt-to-equity ratio of 7.34, a quick ratio of 1.60 and a current ratio of 1.80.

Sanara MedTech (NASDAQ:SMTI) last issued its quarterly earnings results on Wednesday, November 12th. The company reported $0.09 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.33. Sanara MedTech had a negative net margin of 36.79% and a negative return on equity of 21.33%. The company had revenue of $26.33 million during the quarter, compared to the consensus estimate of $26.63 million.

Hedge Funds Weigh In On Sanara MedTech

Several large investors have recently made changes to their positions in the business. Stonebridge Wealth Management LLC acquired a new stake in Sanara MedTech during the second quarter worth about $3,397,000. Marshall Wace LLP boosted its stake in Sanara MedTech by 144.3% during the second quarter. Marshall Wace LLP now owns 71,511 shares of the company’s stock worth $2,030,000 after buying an additional 42,237 shares in the last quarter. Squarepoint Ops LLC increased its holdings in Sanara MedTech by 343.4% in the 3rd quarter. Squarepoint Ops LLC now owns 31,383 shares of the company’s stock valued at $996,000 after buying an additional 24,305 shares during the period. Hsbc Holdings PLC acquired a new position in shares of Sanara MedTech in the 2nd quarter valued at $382,000. Finally, Vanguard Group Inc. boosted its position in shares of Sanara MedTech by 3.4% during the 3rd quarter. Vanguard Group Inc. now owns 182,032 shares of the company’s stock valued at $5,776,000 after acquiring an additional 6,049 shares in the last quarter. Institutional investors and hedge funds own 8.10% of the company’s stock.

About Sanara MedTech

Sanara MedTech is a medical technology company focused on developing and commercializing innovative devices for ear, nose and throat (ENT) healthcare. The company’s core offering centers on minimally invasive sinus dilation systems designed to treat chronic sinusitis and related conditions. These products leverage balloon catheter technology to expand sinus pathways and improve patient outcomes while reducing recovery times. In addition to sinus solutions, the portfolio extends to procedural tools and implants for otology and cranial applications.

With its legacy rooted in the assets of a former Johnson & Johnson business, Sanara MedTech combines decades of research and development in ENT therapies.